Needs/Wishes for Innovation
Businesses looking for similar products or services There are currently no matches found. Please check back at a later time. |
Oral Vaccine for Pets :51552 Painless vacination for pets There are currently no reviews for this Innovation.
| Oral Vaccine for Pets :51552
Painless vacination for pets |
|
The first and only way to mass produce an oral vaccine |
 Annual Sales Forecast for USA * | Innovation Status |
Idea |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
Development
Status |
Proprietary
Protection Status |
Concept
Score |
| Ultra Low |
$3 |
$400,000 |
$2.1 M |
2 of 5
Successful Prototypes
|
5 of 5
Granted Patent Claims
|
56 29 is
Average
|
| Low Support |
$4.6 M |
$11.0 M |
$22.0 M |
| Medium Support |
$37.6 M |
$75.4 M |
$130.2 M |
| High Support |
$102.8 M |
$199.6 M |
$339.1 M |
Remaining Time & Cost to First Sale |
| Ultra High |
$187.4 M |
$367.6 M |
$620.5 M |
1-2 yrs
|
$100M-$250M
|
Oral Vaccine for Pets :51552
- Painless vacination for pets
Final Decision Maker: Owners of Pets in need of vaccinations
Most of the existing micro-sphere oral vaccinations are limited to laboratory use only. A way of mass producing oral vaccines could significantly lower the cost of vaccines, increases drug delivery efficiency, and also avoid the pain, discomfort, security concerns, and fear of inserting syringes to administer vaccines. Vaccinations for pets can be difficult to administer and potentially dangerous for the vet (depending on the animal).
This is the first ever oral vaccine capable of being mass produced at economical levels. Any vaccine can be encapsulated. This is due to a patented co-spray drying method, that can easily be scaled up to meet production needs. The vaccine will only be released upon entry into the stomach, so the likelihood of blood contamination is minimal due to the elimination of invasive administration methods, such as syringes or sprays. This is due to a patented coating material that is PH dependent, ensuring that the vaccine releases only in the stomach, and nowhere else, allowing for safe and easy transportation, storage, and use.
With billions of people and animals in need of vaccinations for numerous diseases, such as polio, malaria, HIV, influenza, and any other virus, this oral vaccine can forever change drug delivery method, completely revolutionizing, and becoming the new standard for the vaccine market.
| $10 for one encapsulation of a vaccine | Seeking: Purchase, Investment, Distribution, Manufacturing/R&D |
|
* Consumption sales forecast. Does not include "Random" events or "Inventory Fill". Forecast is for Year 1 for Large or Year 2 for Small Companies.
Forecast should be read as ..."With Low marketing support there is an 80% odds of achieving sales of at least... |
| Listing #: USA.76.051810.004 |
Page 1 of 4 |
Date Posted: 2010-05-19 |
|
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
Report Assumptions and Inventor(s) Commentary
|
|
| Inventor(s) Assumptions |
"Most Likely"
Estimate |
Confidence |
Inventor(s) Commentary
Data Source or Basis for Assumptions |
| # of Possible Final Decision Makers |
105,000,000 |
50% |
Approx. 170 Million Cats and dogs owned in the united states, each of which averages at least 1 visit per year.
|
| Revenue per First Purchase |
$20.00 |
50% |
Minimum of 1 vaccination per year, average of two with the potential of more depending on how long since last visit to the vet. |
| % that will Repeat |
45% |
40% |
With the ease of administration and low cost in comparison to alternative there would be a fairly high repeat rate. |
| Number of Annual Repeats |
2 |
50% |
Most pet owners bring their pets to the vet for vaccinations and other check ups twice per year on average. |
| Revenue per Repeat Purchase |
$20.00 |
40% |
Price stays level per repeat purchase |
| Reseller (Trade) Margin |
N/A |
N/A |
|
| Producer Profit (EBITD) |
85% |
40% |
After setting up facilities cost per unit would be very low. |
| |
| Innovation Status |
|
Development
Status |
2 of 5
Successful Prototypes
|
the final product is still in developmental stage |
| Cost to First Sale (remaining) |
$100M-$250M |
60% |
based on the price of similar vaccine products found in the markets. estimated cost to do further studies for fda approval and effectiveness |
| Time to First Sale (remaining) |
1-2 yrs |
40% |
to complete testing and build production facility |
| Confidence in Concept Claims made in description |
60% |
The vaccine market is nearly limitless, and will never end, and this is the only known way to mass produce an oral vaccine. |
Proprietary
Protection Status |
5 of 5
Granted Patent Claims
|
|
| Concept Score & Diagnostics |
|
|
| Concept Diagnostics |
Red |
Yellow |
Green |
| Percentile Group |
Bottom 40% |
Middle 40% |
Top 20% |
| Overt Benefit |
 |
|
|
| Reason to Believe |
|
 |
|
| Dramatic Difference |
|
|
 |
|
| Listing #: USA.76.051810.004 |
Page 2 of 4 |
Date Posted: 2010-05-19 |
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
Inventor Commentary & Alternative Development Scenarios
|
|
| Inventor(s) Sales Goals |
| Minimum Goal |
$- |
Current GOAL |
$- |
Inventor(s) Commentary:
NOTE: This innovation is represented by www.yet2.com and was
input by the Planet Eureka! Team who is solely responsible for its
content. All cost and pricing information was estimated by the Planet
Eureka! Team. To access more complete information simply click on “Link
to Website With More Complete Info” or on “Email Inventor(s)” on the
bottom of page 1 of this report. |
|
CURRENT SALES FORECAST |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$3 |
$400,000 |
$2.1 M |
| Low Support |
$4.6 M |
$11.0 M |
$22.0 M |
| Medium Support |
$37.6 M |
$75.4 M |
$130.2 M |
| High Support |
$102.8 M |
$199.6 M |
$339.1 M |
| Ultra High |
$187.4 M |
$367.6 M |
$620.5 M |
If MARKETING CONCEPT Improved (Increase Concept Score by +20 Points) |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$5 |
$550,000 |
$2.9 M |
| Low Support |
$6.3 M |
$15.1 M |
$29.6 M |
| Medium Support |
$51.9 M |
$102.1 M |
$175.6 M |
| High Support |
$140.8 M |
$272.6 M |
$460.4 M |
| Ultra High |
$258.4 M |
$501.6 M |
$847.3 M |
If PRODUCT/SERVICE Improved (Increase Repeat Rate & Number of Repeats by 30% and Revenue Per Purchase 20%) |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$5 |
$580,000 |
$3.1 M |
| Low Support |
$6.5 M |
$15.7 M |
$32.6 M |
| Medium Support |
$53.7 M |
$109.7 M |
$197.8 M |
| High Support |
$143.4 M |
$290.2 M |
$516.2 M |
| Ultra High |
$264.9 M |
$536.7 M |
$961.7 M |
If MARKETING CONCEPT and PRODUCT/SERVICE Improved (Increase Concept +20 Points, Repeat Rate & Number of repeats by 30% and Revenue per purchase 20%) |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$6 |
$790,000 |
$4.4 M |
| Low Support |
$8.9 M |
$21.7 M |
$44.0 M |
| Medium Support |
$74.0 M |
$146.0 M |
$265.6 M |
| High Support |
$192.9 M |
$393.2 M |
$700.0 M |
| Ultra High |
$360.1 M |
$718.9 M |
$1.3 B |
|
| Listing #: USA.76.051810.004 |
Page 3 of 4 |
Date Posted: 2010-05-19 |
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
Additional Details
|
|
| Fair Market Royalty (%) |
| |
Conservative - 80% Odds
Royalty Percentage |
Most Likely - 50% Odds
Royalty Percentage |
Aggressive - 20% Odds
Royalty Percentage |
| At CURRENT State & Status |
13.3% |
15.9% |
18.7% |
Sales & Marketing
Support Level |
Annual Inventor Royalty Revenue |
3 Year Value
to Inventor
If 50% Odds |
| 80% Odds |
50% Odds |
20% Odds |
| Ultra Low Support |
$54,000 |
$130,000 |
$230,000 |
$400,000 |
| Low Support |
$870,000 |
$1.8 M |
$2.9 M |
$5.5 M |
| Medium Support |
$6.4 M |
$11.8 M |
$18.1 M |
$35.4 M |
| High Support |
$17.1 M |
$31.3 M |
$46.5 M |
$93.9 M |
| Ultra High Support |
$31.8 M |
$57.4 M |
$86.2 M |
$172.2 M |
| Sales & Marketing Support Level Assumptions |
| Sales & Marketing Support Level Assumptions |
Sample Numbers |
% Aware x
% Distribution
(Aware & Able) |
Inventor
Confidence |
| % Distribution |
% Awareness |
| Ultra Low Support (Word of Mouth) |
5% |
3% |
0.2% |
N/A |
| Low Support (Small Company) |
20% |
10% |
2% |
N/A |
| Medium Support (Medium Sized Company) |
50% |
25% |
13% |
N/A |
| High Support (Large Company) |
75% |
45% |
34% |
% |
| Ultra High Support (Mega or Niche) |
90% |
70% |
63% |
N/A |
|
Graph of EQUIVALENT (Awareness x Distribution) Combinations
 |
NAICS Industry Codes
For This Invention |
| 33911 - Medical Equipment and Supplies Manufacturing |
| |
| |
| |
| |
|
| Patent Numbers that apply to this Product/Service |
| |
| |
| |
| |
| |
|
| Inventor(s) PEDIGREE |
| Years EXPERIENCE in related industry |
|
| GRANTED Patents |
|
| Licensing Deals SIGNED |
|
| Innovations that have SHIPPED |
|
|
For USA Patents: Utility Patent = 7 digit number, Design Patent starts with D, Planet Patent starts with PP. Provisional Application "61/xxx,xxx", Non provisional application "12/xxx,xxx", Design patent application "29/xxx,xxx"
|
|
CAUTION: This Merwyn Business Simulation Research Report includes no warranty or guarantee. Results and opinions should be considered rough and directional in nature. This is because the report is based upon inventor-supplied data and simplified modeling methods. If you are looking to invest, distribute, purchase or become involved with this innovation, in any way, we strongly urge you to validate the inventor data and sales forecasts BEFORE committing yourself or your resources. Merwyn Research, Inc. shall not be responsible for any liability or damages arising out of the failure to perform such investigation and validation. Changes in the concept description, product, pricing, or input assumptions will almost certainly change results.
|
| Listing #: USA.76.051810.004 |
Page 4 of 4 |
Date Posted: 2010-05-19 |
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
